Remission in Asthma: What Is It? Can It Be Obtained? (AAN)
Price: FREE for members and non-members
Session recorded on November 12, 2024
Speaker: Michael S. Blaiss, MD, FACAAI
With the introduction of new therapies for asthma like biologics, achieving disease remission has become a new goal of treatment and classifying asthma control is in transition. In December 2023, the Annals of Allergy, Asthma & Immunology published a consensus statement between the American College of Allergy, Asthma & Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society to update the definition of clinical remission in asthma. In this webinar, learn more about the consensus statement and the outcomes of the working group.
This program is a collaboration between the American College of Allergy, Asthma & Immunology and the Allergy and Asthma Network (AAN).
Target Audience
Primary Care Providers
Allied Health Professionals
Learning Objectives
Upon completion of this activity learners should be able to:
1. Explain the differences between asthma control and remission.
2. Differentiate the definitions of remission in asthma.
3. Evaluate the basis for the Joint Consensus Statement of the ACAAI, AAAAI, and ATS on remission on treatment in asthma.
All identified relevant financial relationships with ineligible companies have been mitigated.
Speaker:
Michael Blaiss, MD, FACAAI
Consultant: ALK, AstraZeneca, Bryn Pharma, SoundHealth, Hippo DX, Prollergy
Speaker: ALK, AstraZeneca, Regeneron, Sanofi
Advisor: GSK, Regeneron, Sanofi, Hippo DX, Prollergy, Nectar
Moderator:
Lynda Mitchell, Allergy Asthma Network (AAN)
No identified relevant finanical relationships with ineligible companies to disclose
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance